Skip to main content
RAPT Therapeutics, Inc. logo

RAPT Therapeutics, Inc. — Investor Relations & Filings

Ticker · RAPT ISIN · US75382E1091 LEI · 549300MB473BIU78ES48 US Manufacturing
Open in API
Filings indexed 534 across all filing types
Latest filing 2023-04-08 Annual Report
Country US United States of America
Listing US RAPT

About RAPT Therapeutics, Inc.

https://rapt.com/

RAPT Therapeutics, Inc. is a clinical-stage, immunology-based biopharmaceutical company focused on discovering, developing, and commercializing novel therapies for patients with inflammatory and immunologic diseases. The company's scientific approach involves developing therapeutics that intelligently target key drivers of the immune system. Its pipeline includes ozureprubart (RPT904), a long-acting anti-IgE antibody being evaluated in a Phase 2b clinical trial for the treatment of food allergies.

Recent filings

Filing Released Lang Actions
ARS
Annual Report
2023-04-08 English
DEFA14A
Proxy Solicitation & Information Statement Classification · 100% confidence The document is identified as a Schedule 14A filing, which is a proxy statement filed pursuant to Section 14(a) of the Securities Exchange Act of 1934. It is labeled as "Definitive Additional Materials" related to a proxy statement. Proxy statements and related materials are used to provide information to shareholders to solicit their votes for meetings. This matches the definition of Proxy Solicitation & Information Statement (PSI). The document is short (1041 characters) and does not contain financial statements or detailed financial data, so it is not an Annual Report or Management Report. It is not a report publication announcement or regulatory filing fallback. Therefore, the correct classification is PSI.
2023-04-07 English
DEF 14A
Proxy Solicitation & Information Statement
2023-04-07 English
FORM 4 SUBMISSION
Director's Dealing
2023-03-15 English
8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce major events or updates. It includes a press release announcing quarterly and annual financial results and an investor presentation. The document itself is short (4001 characters) and primarily serves as a notification of these events and attachments rather than containing detailed financial statements or analysis. According to the rules, such a filing is best classified as a Regulatory Filing (RNS) because it is a general regulatory announcement and does not contain the full financial report or detailed financial data itself.
2023-03-14 English
10-K
Annual Report FY 2022
2023-03-14 English

Browse filings by year

10 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.